ASCO Virtual Scientific Program, May 29-31, 2020

ASCO Virtual Scientific Program, May 29-31, 2020

ASCO Virtual Scientific Program, May 29-31, 2020 Presentation Schedule for Winship Cancer Institute of Emory University and Emory University School of Medicine Faculty and Trainees Friday, May 29, 2020 Time Session Type Abstract # Presenting Author Senior Author Title 8:00AM - 11:00AM Oral Abstract Session 9000, 9001, 9002 Taofeek K. Owonikoko, MD, Chemo-immunotherapy in Small Cell Lung Cancer: Many Questions Remain PhD, MS (Discussant) 8:00AM - 11:00AM Oral Abstract Session 7503 Muna Qayed, MD, MS Mary Eapen, MD, MS Development and validation of a pediatric disease risk index for allogeneic hematopoietic cell transplantation 8:00AM - 11:00AM Oral Abstract Session 8502 Ajay K. Nooka, MD, MPH Rakesh Popat, MBBS, PhD DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM) 8:00AM - 11:00AM Oral Abstract Session 9000 Ticiana Leal, MD Suresh S. Ramalingam, MD Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES- SCLC): ECOG-ACRIN EA5161. 8:00AM - 11:00AM Oral Abstract Session 9003 Patrick M. Forde, MD Suresh S. Ramalingam, MD PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study 8:00AM - 11:00AM Oral Abstract Session 9500 Suresh S. Ramalingam, MD Julie R. Brahmer, MD Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. 8:00AM - 11:00AM Oral Abstract Session 10504 Kelly C. Goldsmith, MD Yael P. Mosse, MD Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study 8:00AM - 11:00AM Poster Discussion 8511 (Board #411) Jonathan L. Kaufman, MD Nizar J. Bahlis, MD Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and Session dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma 8:00AM - 11:00AM Poster Discussion 9019 (Board #212) Taofeek K. Owonikoko, MD, Gabriel Sica, MD, PhD YAP1 positive small-cell lung cancer subtype is associated with the T-cell inflamed gene Session PhD, MS expression profile and confers good prognosis and long term survival 8:00AM - 11:00AM Poster Discussion 9513 (Board #279) Zofia Piotrowska, MD Suresh S. Ramalingam, MD ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 Session insertions 8:00AM - 11:00AM Poster Discussion 10524 (Board #411) Kelly C. Goldsmith, MD Andrew E. Place, MD The first report of pediatric patients with solid tumors treated with venetoclax. Session 8:00AM - 11:00AM Poster Discussion 6515 (Board #176) Christine H. Chung, MD Nabil F. Saba, MD Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or Session metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study 8:00AM - 11:00AM Poster Session 10541 (Board #428) Thomas Cash, MD Kelly C. Goldsmith, MD A phase I study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors 8:00AM - 11:00AM Poster Session 4583 (Board #191) Walid L. Shaib, MD Bassel F. El-Rayes, MD Adjuvant concurrent chemoradiotherapy in extrahepatic cholangiocarcinoma Time Session Type Abstract # Presenting Author Senior Author Title 8:00AM - 11:00AM Poster Session 1086 (Board #171) Princess Ekpo Manali A. Bhave, MD Outcomes for black versus white women with stage IV breast cancer enrolled on investigator- initiated clinical trials at Emory. 8:00AM - 11:00AM Poster Session 569 (Board #61) Shauna McManus Mylin A. Torres, MD Breast cancer patient reported outcomes, depression, and objective measures of breast cosmesis Poster Session 7079 (Board #351) Olatunji B. Alese, MD Bassel F. El-Rayes, MD A cost analysis of managing cancer-related pain among hospitalized US cancer patients 8:00AM - 11:00AM Poster Session 4068 (Board #60) Katerina Mary Zakka, MD Mehmet Akce, MD Impact of tumor side on clinical outcomes in stage II and III colon cancer with known microsatellite instability status. 8:00AM - 11:00AM Poster Session TPS9082 (Board Helen J. Ross, MD Jeffrey Bradley, MD NRG Oncology/Alliance LU005: A phase II/III randomized clinical trial of chemoradiation #275) versus chemoradiation plus atezolizumab in limited stage small cell lung cancer 8:00AM - 11:00AM Poster Session 7022 (Board #294) Eli Rowe Abernethy Rebecca Pentz, PhD Videos improve patient understanding of misunderstood chemotherapy terms in a rural population 8:00AM - 11:00AM Poster Session 7042 (Board #314) Xu Ji, PhD, MSPH Karen Effinger, MD National estimates of substance use, substance use disorders, and treatment among adolescent and young adult cancer survivors 8:00AM - 11:00AM Poster Session 3596 (Board #326) Jia Yao, PhD Dmitry Shayakhmetov, PhD Tumor-targeted oncolytic adenovirus demonstrates high cytotoxicity for human lung and renal cell carcinomas independently of the level of tumor PD-L1 expression 8:00AM - 11:00AM Poster Session 10061 (Board #410) Michael C. Lowe, MD, MA Ragini R. Kudchadkar, MD Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma 8:00AM - 11:00AM Poster Session 5061 (Board #130) Mehmet Asim Bilen, MD Toni Choueiri, MD Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101 8:00AM - 11:00AM Poster Session 6054 (Board #225) Mehmet Akce, MD Cindy O'Bryant, PharmD, Pharmacokinetics and safety following a single oral dose of niraparib in patients with BCOP moderate hepatic impairment 8:00AM - 11:00AM Poster Session 2043 (Board #35) Yasmin Karimi, MD Imon Banerjee, PhD Development and validation of natural language processing (NLP) algorithm for detection of distant versus local breast cancer recurrence and metastatic site 8:00AM - 11:00AM Poster Session 7041 (Board #313) Gelareh Sadigh, MD Ruth C. Carlos, MD, MS Breast cancer patients’ insurance status correlates with their adherence to endocrine therapy: Analysis of ECOG-ACRIN TAILORx trial 8:00AM - 11:00AM Poster Session TPS8067 (Board Sharon M. Castellino, MD, Kara Kelly. MD An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in #400) MSc adolescents and young adults (AYA): SWOG S1826 8:00AM - 11:00AM Poster Session 8535 (Board #435) Douglas W. Sborov, MD, MS Craig C. Hofmeister, MD Oncolytic virus pelareorep plus carfilzomib phase I trial in carfilzomib-refractory patients (NCI 9603): Responses with cytokine storm 8:00AM - 11:00AM Poster Session 8536 (Board #436) Sagar Lonial, MD Adam D. Cohen, MD Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs) 8:00AM - 11:00AM Poster Session TPS9079 (Board Andreas Rimner Jeffrey Bradley, MD A phase III randomized trial of pleurectomy/decortication plus chemotherapy with or without #272) adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for malignant pleural mesothelioma (MPM) (NRG LU-006) 8:00AM - 11:00AM Poster Session TPS9080 (Board Taofeek K. Owonikoko, MD, Marie-Anne Damiette Smit, MD Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune #273) PhD, MS therapy) targeting DLL3, in patients with small cell lung cancer (SCLC). Saturday, May 30, 2020 Time Session Type Abstract # Presenting Author Winship Collaborator Title 8:00AM - 11:00AM Poster Session 8527 (Board #427) Meletios A. Dimopoulos, MD Sagar Lonial, MD Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT): The phase III TOURMALINE-MM4 trial 10:30AM Highlights of the Day Nabil F. Saba, MD Head and Neck Cancer Session (Discussant) 4:30PM - 5:30PM Clinical Science LBA110 Jeremy Lyle Warner, MD, MS Mehmet Asim Bilen, MD Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Symposium Consortium (CCC19) Sunday, May 31, 2020 Time Session Type Abstract # Presenting Author Winship Collaborator Title 10:30AM - 12:00PM Clinical Science 107 Ami Vijay Desai, MD, MSCE Thomas Cash, MD Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, Symposium including primary CNS tumors. 1:00PM - 4:00PM Plenary Session LBA3 Shaji Kumar, MD Sagar Lonial, MD Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial. Published Abstracts Type Abstract # Presenting Author Senior Author Title Published Abstract e18522 Melissa Taylor Nabil F. Saba, MD Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population: A SEER based analysis from 2000-2016. Published Abstract e22002 Mohammad K. Khan, MD, Rafi Ahmed, PhD Interim results of prospective pilot phase II trial of concurrent anti-PD-1 and stereotactic PhD radiosurgery (SRS) for melanoma and NSCLC patients with brain metastases (NCT02858869). Published Abstract

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    4 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us